141 related articles for article (PubMed ID: 36858191)
1. Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Szymczak B; Czarnecka J; Czach S; Nowak W; Roszek K
Cell Signal; 2023 Jun; 106():110641. PubMed ID: 36858191
[TBL] [Abstract][Full Text] [Related]
2. Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Oliveira KA; Dal-Cim TA; Lopes FG; Nedel CB; Tasca CI
Purinergic Signal; 2017 Sep; 13(3):305-318. PubMed ID: 28536931
[TBL] [Abstract][Full Text] [Related]
3. Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Pinto F; Costa ÂM; Andrade RP; Reis RM
Neurotherapeutics; 2020 Oct; 17(4):2015-2027. PubMed ID: 32785847
[TBL] [Abstract][Full Text] [Related]
4. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Wei Y; Duan S; Gong F; Li Q
Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
7. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
8. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
9. Bivalent activity of super-enhancer RNA LINC02454 controls 3D chromatin structure and regulates glioma sensitivity to temozolomide.
Shi T; Guo D; Zheng Y; Wang W; Bi J; He A; Fan S; Su G; Zhao X; Zhao Z; Song Y; Sun S; Li P; Zhao Z; Shi J; Lu W; Zhang L
Cell Death Dis; 2024 Jan; 15(1):6. PubMed ID: 38177123
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Oliveira KA; Dal-Cim T; Lopes FG; Ludka FK; Nedel CB; Tasca CI
Mol Neurobiol; 2018 Feb; 55(2):1509-1523. PubMed ID: 28181188
[TBL] [Abstract][Full Text] [Related]
11. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
12. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Wu Y; Yao Y; Yun Y; Wang M; Zhu R
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31409725
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
15. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
16. Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Li M; Ren T; Lin M; Wang Z; Zhang J
J Proteomics; 2020 Jan; 211():103578. PubMed ID: 31689562
[TBL] [Abstract][Full Text] [Related]
17. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
18. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
19. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
20. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]